CYT997, also known as Lexibulin, is a small molecule anticancer agent that belongs to the family of vascular disrupting agents (VDAs). The chemical name of CYT997 is (Z)-5-((4-bromo-2-(1H-indol-3-yl)pyrimidin-5-yl)amino)-1-cyclopropyl-3-methyl-1H-pyrazole-4-carboxamide. The molecular formula of CYT997 is C19H15BrN6O and its formula weight is 438.27. The CAS No of CYT997 is 917111-44-5.
Top Ten Keywords and Synonyms:
Synonyms: (Z)-5-((4-bromo-2-(3H-indol-3-yl)pyrimidin-5-yl)amino)-1-cyclopropyl-3-methyl-1H-pyrazole-4-carboxamide; CYT997; Lexibulin.
Health Benefits of CYT997:
CYT997 has been found to exhibit potential health benefits in several preclinical and clinical studies, including:
Anticancer activity: CYT997 possesses significant anticancer activity against a variety of cancer types, such as breast, lung, colon, and pancreatic cancer.
Reduced tumor angiogenesis: CYT997 has been demonstrated to reduce tumor angiogenesis by selectively disrupting the pre-existing tumor blood vessels.
Attenuated metastasis: CYT997 can potentially attenuate metastasis by reducing the tumor microenvironment and suppressing the migration and invasion of cancer cells.
Potential Effects of CYT997:
CYT997 is a potent vascular disrupting agent, and thus it may exhibit potential effects in various disease conditions, such as cancer and other vascular disorders.
Cancer treatment: CYT997 can induce significant tumor vascular disruption and necrosis, leading to reduced tumor growth, metastases, and improved patient survival rates.
Vascular disorders: CYT997 has been found to selectively disrupt pre-existing abnormal blood vessels, suggesting its potential use in the treatment of vascular disorders.
CYT997 is a potent vascular disrupting agent that selectively targets the pre-existing tumor vasculature, leading to tumor blood vessel damage, collapse, and destruction. The depletion of the tumor blood vessels leads to tumor ischemia and hypoxia, which results in tumor necrosis and reduced tumor size. In addition, CYT997 has been demonstrated to inhibit the proliferation and migration of cancer cells by altering the tumor microenvironment.
CYT997 has been extensively studied in preclinical and clinical trials, and it has been found to be generally safe and well-tolerated, with a low toxicity profile.
The most common side effects of CYT997 reported in clinical trials include:
The dosing information of CYT997 varies depending on the specific clinical trial and indication. However, the typical dose of CYT997 ranges from 1-4 mg/m2 given once weekly, to 20-40 mg/m2 given every 3-4 weeks.
CYT997 is a potent vascular disrupting agent that exhibits potential therapeutic benefits in cancer treatment and other vascular disorders. Its safety and efficacy have been demonstrated in several preclinical and clinical studies. CYT997 holds great promise as a potential therapeutic agent for various diseases, but more research is needed to fully understand its mechanisms of action and clinical applications.